POSITION STATEMENTS
For General Public
POSITION STATEMENTS
For General Public
August 26, 2010
Osteoporosis Canada statement on esophageal cancer and bisphosphonate use
No link between the use of bisphosphonates and the risk of cancer of the esophagus or stomach has also been noted in a recent large study from the UK. This […]
July 14, 2009
THE REPORTED ASSOCIATION BETWEEN USE OF ZOLEDRONIC ACID (ACLASTA) AND RENAL IMPAIRMENT
We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]
January 22, 2008
Osteonecrosis of bone: Our team of experts weighs in
Last week, Osteoporosis Canada heard a news story that suggested that there is an increased risk of developing osteonecrosis of bone if you are taking a bisphosphonate medication for osteoporosis. […]
June 13, 2007
Osteonecrosis of the Jaw
A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]
August 26, 2010
Osteoporosis Canada statement on esophageal cancer and bisphosphonate use
No link between the use of bisphosphonates and the risk of cancer of the esophagus or stomach has also been noted in a recent large study from the UK. This […]
July 14, 2009
THE REPORTED ASSOCIATION BETWEEN USE OF ZOLEDRONIC ACID (ACLASTA) AND RENAL IMPAIRMENT
We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]
January 22, 2008
Osteonecrosis of bone: Our team of experts weighs in
Last week, Osteoporosis Canada heard a news story that suggested that there is an increased risk of developing osteonecrosis of bone if you are taking a bisphosphonate medication for osteoporosis. […]
June 13, 2007
Osteonecrosis of the Jaw
A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]